SCL Science Inc. (KOSDAQ:246960)

Market Cap	71.95B +1.5%
Revenue (ttm)	16.32B +488.8%
Net Income	-3.66B
EPS	-123.25
Shares Out	34.02M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,051
Average Volume	58,392
Open	2,110.00
Previous Close	2,110.00
Day's Range	2,100.00 - 2,195.00
52-Week Range	1,882.50 - 5,110.00
Beta	0.71
RSI	40.92
Earnings Date	Mar 20, 2026

About SCL Science

SCL Science Inc. produces medical hemostatic agents using biomimetic technology. Its products include BiMM (Bio-inspired Medical Materials) that reacts immediately with blood; Endoseal, which is used for specialized indication of gastrointestinal bleeding; InnoSeal, a hemostatic agent that is used in various surgical fields, such as cardiology, radiology, and neurosurgery; Jelly Seal, a hemostasis and sealing products; STOP, a non-bleeding intravascular injection; Film that prevents leakage at intestinal and vascular anastomosis sites; InnoLOCK...

• Industry: Orthopedic, Prosthetic, and Surgical Appliances and Supplies
• Founded: 2010
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 246960

Financial Performance

In 2024, SCL Science's revenue was 4.74 billion, an increase of 258.30% compared to the previous year's 1.32 billion. Losses were -3.73 billion, -25.79% less than in 2023.